Investment Column: Cobham is more than just defensive

Immunodiagnostic Systs; Eckoh


Our view: Buy

Share price: 274.6p (-0.7p)

At first glance, two concerns spring to mind when looking at Cobham, the defence and aerospace electronics group. First, the world economy seems to be recovering from the financial crisis and traders are increasingly on the prowl for companies that track the rhythms of the economy. Cobham isn't one of them. Like others in the sector, it is a defensive play, which is a great attribute but means that the growth of the shares could be pedestrian as the recovery takes hold.

The second concern stems from the likelihood of cuts in defence spending, both here and in the US, as governments battle to contain yawning deficits and stave off the threat of credit ratings downgrades. That said, Cobham still offers exposure to some high growth areas such as intelligence, surveillance and cyber-security. Morgan Stanley says this should allow it to grow earnings at a compounded annual rate of 10 per cent over the three years to 2012. If achieved, that would put it well ahead of its peers.

It is also worth noting that the auguries are promising; investors need only look to the recent full-year results, which evidenced healthy rises in profits and revenues. So investors are faced with a dilemma, with the risk of some near-term pressure as traders switch out of defensives, coupled with the prospect of budget cuts, balanced against an evidently strong company with the potential for what could be strong growth.

It all comes down to valuation, which leaves little room for doubt. Cobham trades on a surprisingly thin multiple of 11.6 times Evolution's forecasts for 2010. That falls to 10.8 times on the numbers for 2011, suggesting that the market may be pricing in too much disappointment while at the same time overlooking the potential for growth. We said buy in November last year and, given the stock's attractive valuation, we say keep buying.



Immunodiagnostic Systs

Our view: Buy on weakness

Share price: 730p (-15p)

Immunodiagnostic Systems might sound vaguely like some flaky biotechnology stock but it is actually a solid company that makes diagnostic testing kits for the clinical and research markets. And yesterday's trading update had much to like about it, not least the fact that it beat Panmure's forecast revenues (£37.1m against £35.1m). Said revenues are 49 per cent up on the previous year and ahead in all of the company's diverse markets. Profits will be solidly in line with expectations too.

So, then, why the fall in the share price? Well, the problem is getting approval from the US Food and Drug Administration (USFDA) for the automated immuno-analyser IDS-iSYS. The company notes that approval times are lengthening, but it is still worrying and arguably grounds for caution about the stock, which would move into sharp reverse if the delay turned into something more worrying. It is also true that the shares have had a good run in recent months.

Panmure has Immunodiagnostic Systems on 16.9 times 2011 full-year earnings, which looks pricey, but is much more reasonable when compared to the company's peer group. The issue with the USFDA remains a worry for investors but the company generally looks in good shape and, if the shares fall further over the coming days, investors willing to take a risk should be prepared to take advantage. Buy on weakness.



Eckoh

Our view: Hold for now

Share price: 4.75p (Unchanged)

Eckoh provides what it calls "hosted speech recognition services" – those robot voices on the end of a telephone booking line. The next time you are negotiating with a machine to buy Vue cinema tickets, you will be talking to Eckoh. The company has changed hugely since it was founded in 1993 and is backing its "Speech Solution" operation to provide its main growth.

It may be a small operation but the client list includes some big names including National Rail Enquiries, the bookmaker William Hill, Parcelforce Worldwide and mobile phone operator O2. It also provided the automated phone-in lines for Comic Relief.

At the interim results in December, Eckoh reported that turnover in speech had risen 15 per cent year on year. Yet, the revenues declined overall because of a slide in the larger side of the business, the so-called Client IVR, or premium-rate phone services. Revenues in that division fell 28 per cent after it lost ITV as a client in December 2008, and IVR calls have further reduced as publishing clients have gone out of business. The future doesn't look great for the division, and management admit the market has been on a downward slope for a couple of years. Eckoh's speech business looks good but IVR issues worry us. Still, the shares are cheap, so hold for now.

Suggested Topics
Start your day with The Independent, sign up for daily news emails
PROMOTED VIDEO
News
ebooksNow available in paperback
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Ashdown Group: Marketing Services Manager - (communications, testing, DM)

£32000 - £35000 per annum + benefits: Ashdown Group: Marketing Services Manage...

Guru Careers: Finance Account Manager

£Neg. (DOE) + Excellent Benefits: Guru Careers: A Finance Account Manager with...

Ashdown Group: Java Developer - Hertfordshire - £47,000 + bonus + benefits

£40000 - £470000 per annum + bonus: Ashdown Group: Java Developer / J2EE Devel...

Ashdown Group: Direct Marketing Manager - B2C, Financial Services - Slough

£45000 - £55000 per annum + Benefits: Ashdown Group: An exciting opportunity h...

Day In a Page

Jeb Bush vs Hillary Clinton: The power dynamics of the two first families

Jeb Bush vs Hillary Clinton

Karen Tumulty explores the power dynamics of the two first families
Stockholm is rivalling Silicon Valley with a hotbed of technology start-ups

Stockholm is rivalling Silicon Valley

The Swedish capital is home to two of the most popular video games in the world, as well as thousands of technology start-ups worth hundreds of millions of pounds – and it's all happened since 2009
Did Japanese workers really get their symbols mixed up and display Santa on a crucifix?

Crucified Santa: Urban myth refuses to die

The story goes that Japanese store workers created a life-size effigy of a smiling "Father Kurisumasu" attached to a facsimile of Our Lord's final instrument of torture
Jennifer Saunders and Kate Moss join David Walliams on set for TV adaptation of The Boy in the Dress

The Boy in the Dress: On set with the stars

Walliams' story about a boy who goes to school in a dress will be shown this Christmas
La Famille Bélier is being touted as this year's Amelie - so why are many in the deaf community outraged by it?

Deaf community outraged by La Famille Bélier

The new film tells the story of a deaf-mute farming family and is being touted as this year's Amelie
10 best high-end laptops

10 best high-end laptops

From lightweight and zippy devices to gaming beasts, we test the latest in top-spec portable computers
Michael Carberry: ‘After such a tough time, I’m not sure I will stay in the game’

Michael Carberry: ‘After such a tough time, I’m not sure I will stay in the game’

The batsman has grown disillusioned after England’s Ashes debacle and allegations linking him to the Pietersen affair
Susie Wolff: A driving force in battle for equality behind the wheel

Susie Wolff: A driving force in battle for equality behind the wheel

The Williams driver has had plenty of doubters, but hopes she will be judged by her ability in the cockpit
Adam Gemili interview: 'No abs Adam' plans to muscle in on Usain Bolt's turf

'No abs Adam' plans to muscle in on Usain Bolt's turf

After a year touched by tragedy, Adam Gemili wants to become the sixth Briton to run a sub-10sec 100m
Calls for a military mental health 'quality mark'

Homeless Veterans campaign

Expert calls for military mental health 'quality mark'
Racton Man: Analysis shows famous skeleton was a 6ft Bronze Age superman

Meet Racton Man

Analysis shows famous skeleton was a 6ft Bronze Age superman
Garden Bridge: St Paul’s adds to £175m project’s troubled waters

Garden Bridge

St Paul’s adds to £175m project’s troubled waters
Stuff your own Christmas mouse ornament: An evening class in taxidermy with a festive feel

Stuff your own Christmas mouse ornament

An evening class in taxidermy with a festive feel
Joint Enterprise: The legal doctrine which critics say has caused hundreds of miscarriages of justice

Joint Enterprise

The legal doctrine which critics say has caused hundreds of miscarriages of justice
Freud and Eros: Love, Lust and Longing at the Freud Museum: Objects of Desire

Freud and Eros

Love, Lust and Longing at the Freud Museum